Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05306353 · ClinicalTrials.gov registry record · Phase 2
CD40L Antagonism in Rheumatoid Arthritis (RA)
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05306353 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2 participants.
The verdict
NCT05306353, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Interventions
- DRUG Placebo for VIB4920
- DRUG VIB4920 with TNFi
- DRUG VIB4920 without TNFi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2025-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05306353
The ClinicalTrials.gov registry entry for NCT05306353 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo for VIB4920 is the first listed.
NCT05306353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05306353 about?
NCT05306353 is a clinical study titled "CD40L Antagonism in Rheumatoid Arthritis (RA)". The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
What is the current status of trial NCT05306353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-07-25. Estimated completion is 2025-07-28.
What interventions are being tested in trial NCT05306353?
The interventions under investigation include: Placebo for VIB4920 (DRUG), VIB4920 with TNFi (DRUG), VIB4920 without TNFi (DRUG).
Who is sponsoring clinical trial NCT05306353?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.